Showing results (71-80 of 453) with videos related to
Sort By:
Pageof 46
Current Problems in Cancer|July 1, 2017
Targeting ATR in cancer medicineRaghav Sundar, Jessica Brown, Alvaro Ingles Russo, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
Novel Synthetic Lethal Therapeutic Strategies in Precision OncologyTimothy A Yap, Fiona Simpkins, Marie Porte, et al.Expert Review of Anticancer Therapy|October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancerTimothy A Yap, Carmel J Pezaro, Johann S de BonoCurrent Opinion in Oncology|July 5, 2022
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinationsNatalie Y L Ngoi, Shannon N Westin, Timothy A YapEuropean Journal of Cancer (Oxford, England : 1990)|November 21, 2009
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspectiveShahneen K Sandhu, Timothy A Yap, Johann S de BonoCurrent Drug Targets|July 23, 2011
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatmentShahneen K Sandhu, Timothy A Yap, Johann S de BonoThe Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.International Journal of Medical Informatics|September 5, 2020
Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effortAlejandro Araya, Jia Zeng, Amber Johnson, et al.Nature Reviews. Clinical Oncology|August 10, 2011
The changing therapeutic landscape of castration-resistant prostate cancerTimothy A Yap, Andrea Zivi, Aurelius Omlin, et al.Pageof 46